m+Medelevator.RU
← Поиск публикаций
Research square · 2024

Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining.

СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Godinez-Macias Karla P, Chen Daisy, Wallis J Lincoln, Siegel Miles G, Adam Anna, Bopp Selina, Carolino Krypton, Coulson Lauren B, Durst Greg, Thathy Vandana, Esherick Lisl, Farringer Madeline A, Flannery Erika L, Forte Barbara, Liu Tiqing, Magalhaes Luma Godoy, Gupta Anil K, Istvan Eva S, Jiang Tiantian, Kumpornsin Krittikorn, Lobb Karen, McLean Kyle, Moura Igor M R, Okombo John, Payne N Connor, Plater Andrew, Rao Srinivasa P S, Siqueira-Neto Jair L, Somsen Bente A, Summers Robert L, Zhang Rumin, Gilson Michael K, Gamo Francisco-Javier, Campo Brice, Baragaña Beatriz, Duffy James, Gilbert Ian H, Lukens Amanda K, Dechering Koen J, Niles Jacquin C, McNamara Case W, Cheng Xiu, Birkholtz Lyn-Marie, Bronkhorst Alfred W, Fidock David A, Wirth Dyann F, Goldberg Daniel E, Lee Marcus C S, Winzeler Elizabeth A

Аннотация

The identification of novel drug targets for the purpose of designing small molecule inhibitors is key component to modern drug discovery. In malaria parasites, discoveries of antimalarial targets have primarily occurred retroactively by investigating the mode of action of compounds found through phenotypic screens. Although this method has yielded many promising candidates, it is time- and resource-consuming and misses targets not captured by existing antimalarial compound libraries and phenotypic assay conditions. Leveraging recent advances in protein structure prediction and data mining, we systematically assessed the Plasmodium falciparum genome for proteins amenable to target-based drug discovery, identifying 867 candidate targets with evidence of small molecule binding and blood stage essentiality. Of these, 540 proteins showed strong essentiality evidence and lack inhibitors that have progressed to clinical trials. Expert review and rubric-based scoring of this subset based on additional criteria such as selectivity, structural information, and assay developability yielded 67 high priority candidates. This study also provides a genome-wide data resource and implements a generalizable framework for systematically evaluating and prioritizing novel pathogenic disease targets.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты